You just read:

Grünenthal and Akashi Therapeutics Inc. Announce Joint Drug Development Program for HT-100 in the Treatment of Patients with Duchenne Muscular Dystrophy (DMD)

News provided by

Grunenthal Pharma GmbH & Co. KG.

08 Jan, 2016, 12:00 GMT